Authored By: Sarah
11 Jul 2024

 Rapid Microbiology Testing Market Size to grow by USD 2,487.91 million between 2023-2027

According to a research report “ Rapid Microbiology Testing Market” by End-user (Hospitals and diagnostic laboratories, Pharmaceutical and biotechnology companies, Others) Geography (North America, Asia, Europe, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 2,487.91 million, at a CAGR of  9.31% during the forecast period. The rise in the prevalence of infectious diseases, including HIV, tuberculosis, pneumonia, and malaria, necessitates rapid microbiology testing to ensure timely diagnosis and effective treatment. HIV, for instance, weakens the immune system, making individuals more susceptible to secondary infections like tuberculosis and pneumonia. Awareness programs, such as the Aid for AIDS, aim to encourage preventive healthcare and early diagnosis through access to necessary treatments and tools. Enhancing diagnostic capabilities is crucial to mitigate the health risks associated with compromised immune systems.

Browse market data tables, figures, and in-depth TOC on “Rapid Microbiology Testing Market” by End-user (Hospitals and diagnostic laboratories, Pharmaceutical and biotechnology companies, Others) Geography (North America, Asia, Europe, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample


By End-user, the Hospitals and diagnostic laboratories segment is projected to dominate the market size in 2024


By Geography, North America  segment is expected to hold the largest market size for the year 2024

In the realm of microbiology testing, growth-based methods distinguish themselves from conventional culture techniques by utilizing biochemical or physiological indicators instead of visible microbial growth for detection. This approach enables faster results, albeit requiring a brief enrichment phase for contamination with low microbial loads. Growth-based testing offers quantitative cell count data, viable cell concentration estimations, microorganism presence information, and microbial identification. The growth-based microbiology testing segment commands the largest market share due to the growing demand for early infectious disease detection, maintaining its market dominance throughout the forecast period.

North America is forecasted to hold the largest market size by region in 2024

In the global rapid microbiology testing market, North America holds the largest revenue share in 2022, primarily driven by the US and Canada. The region's market growth can be attributed to the heightened focus on drug discovery and development, advanced biotechnology and pharmaceutical research, and the presence of numerous vendors providing comprehensive microbial testing solutions. Notable companies, such as Novartis and Pfizer, based in the US, are significantly contributing to this growth due to their extensive research and development activities in the pharmaceutical sector, which necessitate microbial testing for drug development and disease diagnosis.

The Rapid Microbiology Testing Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • Becton Dickinson and Co.
  • bioMerieux SA
  • Biosensia Ltd.
  • Bruker Corp.
  • Charles River Laboratories
  • Colifast AS
  • Danaher Corp.
  • Don Whitley Scientific Ltd.
  • Euroclone SpA
  • Gradientech AB
  • Merck KGaA
  • Neogen Corp.
  • Quidel Corp.
  • Rapid Micro Biosystems Inc.
  • rqMicro AG
  • Sartorius AG
  • Serosep Ltd.
  • Solus Scientific Ltd.
  • Thermo Fisher Scientific Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Rapid Microbiology Testing Market is witnessing significant growth due to the increasing demand for advanced technology solutions in the healthcare industry. Companies like Illumina are leading the way with innovative technologies and offerings, including consumables, reagents, and kits for microbial identification and susceptibility testing. These tests play a crucial role in the development of IVDs and diagnostic manufacturers, particularly in clinical trials and drug discovery. Regulators are driving the need for rapid and accurate microbiology testing, with stringent regulations for the validation of these tests. Small companies are entering the market with cost-effective solutions, challenging the dominance of larger players. Advanced technology instruments are becoming increasingly important for microbial screening in areas such as pneumonia, malaria, tuberculosis, HIV, and cancer. Capital investments in microbiology techniques are on the rise, with a focus on improving the cost-benefit ratio and reducing drug attrition. The industry is expected to continue its growth trajectory, driven by the need for rapid and accurate testing in clinical and research settings.

Market Research Overview

The Rapid Microbiology Testing Market encompasses a range of diagnostic test kits used to detect microorganisms in various industries, including pharmaceuticals, healthcare, cosmetics, food, beverages, and environmental testing. The market is driven by the need for quick and accurate identification of microbes, especially in the context of drugs, therapeutic respiratory products, and clinical disease diagnostics. Skilled laboratory professionals employ various methods such as sensitivity-based rapid microbiology testing, viability-based, nucleic acid-based, cellular component-based, and growth-based techniques. These tests use advanced technology like NGS (Next-Generation Sequencing) and RNA, DNA, and nucleotide-based gene testing. The market is witnessing significant growth due to increasing healthcare expenditure, regulatory requirements, and the development of IVD (In Vitro Diagnostic) tests by diagnostic manufacturers. Small companies and clinical laboratories invest in capital-intensive instruments, consumables, reagents, and kits for rapid tests. Rapid microbiology testing plays a crucial role in drug discovery, clinical trials, and validation, reducing drug attrition and improving the cost-benefit ratio. Applications include the detection of microbes causing diseases like pneumonia, malaria, tuberculosis, HIV, and cancer.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!